🔗 Share this article

Given that the US undertakes historic adjustments to its immunization recommendations, one figure has emerged in a surprising turn: Tracy Beth Høeg, a US-based physician and public health researcher who rose to prominence by questioning Covid vaccines in the global health crisis and has focused upon alleged fatalities following Covid vaccination in her short tenure at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Schedule

Public health authorities planned to announce sweeping revisions to the childhood vaccine schedule earlier this month, bringing the US with the Danish vaccine program, it is understood – a significant shift that would place the US out of step with many the global community with no evidence for improved outcomes. This reveal has been delayed until the coming year.

In place of Vinay Prasad, Høeg is scheduled to present at the gathering. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth person to lead the division this year.

Consolidating Power at the Agency

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad solidify control at the agency – and it signals a greater focus upon dismantling long-standing immunizations at the FDA.

Høeg has often pushed for discontinuing some pediatric vaccine recommendations in the US to become more in line with Denmark's approach, a nation with universal health coverage and a population roughly the size of the state of Wisconsin.

To date statements, she has kept her attention on vaccination policy – typically the responsibility of Dr. Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Qualifications

The appointee has no apparent track record in pharmaceutical research, approval processes or management, which has been standard for past directors of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for leading the CDER, stated Dr. Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in managing a sizeable institution. She is not an expert in industry regulation.”

Former heads of CBER would “grasp regulatory frameworks and the research of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she lacks the type of experience that former directors who ran the center have had.”

CDER has an vast workload at the agency, she emphasized.

“Everybody just focuses on the novel medication approvals, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and other areas, and all of those have to be looked after,” she said. “The area you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial leadership element to the job, which manages over 5,000 employees. “It’s a huge administrative position, if you execute it properly,” she added.

Response and Controversial Initiatives

In response to concerns about Høeg’s fitness for the role and whether this assignment represents more teamwork among regulatory chiefs on vaccines, a representative stated that the “concerns rely on flawed premises”.

“Her experience matches the duties of her position,” the official explained, citing the period Dr. Høeg spent counseling the agency head on “drug safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg takes over the agency head's recently launched fast-track approval initiative, a disputed expedited drug-approval program that allegedly worried her predecessors. “How are these therapies being picked for this expedited pathway? Who makes the calls?” Howard said. “There’s a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he remarked, “the agency looks to be trending towards less stringent oversight of most medications, with the exception of immunizations.”

Documented Past Work on Immunizations

With immunizations, Høeg has a clearer, if concerning, history, Howard said. She released a analysis using unverified volunteer-provided data to determine the rate of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccines are riskier than they are.

Part of her “wish list” for the new administration encompassed changing regulations for recently developed shots and halting “non-essential” vaccines, she remarked after the election on a audio program. At the FDA, Dr. Høeg has reportedly proposed barring adolescent males from getting COVID-19 vaccines.

“She is an complete dogmatist who starts off with her preconceived notions and reverse-engineers to retrofit the data in a very deceptive, untruthful fashion,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with fellow dissenters, {like|